Drs. Julie Schulz and Michael Dovidio recently appeared on Urban Health Today to discuss how lab values, such as hemoglobin A1C, are transforming coverage decisions for GLP-1 drugs used in diabetes and obesity treatment. Unlike traditional metrics like BMI, lab values provide a more accurate and comprehensive understanding of cardiometabolic health, enabling healthcare providers to deliver more targeted and equitable care.

This innovative approach highlights the critical role of lab-based insights in optimizing treatment outcomes and improving access to life-changing therapies for patients with complex health needs. 

Learn more about how these advancements are reshaping care delivery and access the full episode at Urban Health Today.